Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 2 Study of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., Nov. 18, 2011 /PRNewswire/ --  Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic non-small cell lung cancer (NSCLC). 

(Logo: )

The Phase 2 study is designed to estimate Progression Free Survival (PFS) when combining MM-121 and erlotinib in three distinct metastatic NSCLC patient populations:

  • Group A includes patients whose tumors do not have an EGFR activating mutation.  The patient's cancer must have recurred or progressed following at least one chemotherapy-containing regimen and who have not received prior EGFR targeted therapy. They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group B includes patients whose tumors have an EGFR activating mutation.  The patients must have not received prior EGFR targeted therapy.  They will be randomized to receive either MM-121 in combination with erlotinib or erlotinib alone.
  • Group C includes patients whose tumors had responded to EGFR targeted therapy and have subsequently acquired resistance. They will receive MM-121 in combination with erlotinib.

The study is being conducted at multiple sites in North America, Europe and Asia. The trial is designed to enroll approximately 229 patients across all three arms.  The first patient was enrolled at the Loma Linda University Cancer Center.

Merrimack entered into an exclusive, global collaboration and licensing agreement with Sanofi for MM-121 in 2009.

About Merrimack 

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process.  Merrimack currently has four targeted therapeutic oncology candidates in clinical development and a fifth expected to enter clinical development by early 2012.

Contact:  Kathleen Petrozzelli Gallagher, Corporate Communications, Merrimack, 617-441-1043,
Betsy Stevenson, RaymondStevenson Healthcare Communications, 860-984-1424,

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Programs from Merrimack Pharmaceuticals Pipeline to be Presented at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
3. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
4. Merrimack Pharmaceuticals Announces that Recruitment is Open in a Phase 1 Combination Study of MM-111 with Multiple Treatment Regimens in HER2 Positive Patients
5. Merrimack Pharmaceuticals Announces the Addition of Michael Porter to its Board of Directors
6. Merrimack Pharmaceuticals to Present at the 2010 Stifel Nicolaus Healthcare Conference
7. Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-ErbB3 Monoclonal Antibody
8. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
9. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
10. Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases
11. Idenix Pharmaceuticals Prices Public Offering of Common Stock
Post Your Comments:
(Date:11/24/2015)... Avery Biomedical Devices (ABD), manufacturer of the ... appointment of Anders Jonzon , MD; Ph.D. as ... Dr. Jonzon is a Physiologist and consultant ... University, Uppsala and Children,s Hospital, Karolinska, Stockholm, ... at the Cardiovascular Institute (UCSF). His research has covered ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... Education and Human Resources will be presenting in the upcoming ... Plan Strategies for a Dynamic Market" on Dec. 1, 2015. ... consultant with the Cambridge Advisory Group, where she leads their ... The webinar will discuss the rapid growth of oral oncolytics, ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , has ... new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea ... have opened a Koala Center for Sleep Disorders in the US, one of four in ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... and Healthy Aging Program have announced their endorsement of the Medical Fitness ... Health Fitness is proud to have the MFN as one of our endorsed ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Autism Speaks, the ... global movement driven by social media and the generosity of people around the world. ... their social media networks to give – and share the personal stories behind those ...
(Date:11/24/2015)... Miami, FL (PRWEB) , ... November 24, 2015 ... ... manufacturer and engineer of patented products, announces Innovative Blending, a household invention that ... go. , "The Juice & Smoothie Bars market is worth $2 billion," says ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager CEO of PharmMD, has ... past year there have been multiple breakthroughs and challenges as healthcare reform moves out ... enabled their customers and partners to stay ahead of the curve by breaking down ...
Breaking Medicine News(10 mins):